LEADER 04637nam 2201249z- 450 001 9910557304003321 005 20231214133045.0 035 $a(CKB)5400000000042816 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76438 035 $a(EXLCZ)995400000000042816 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPaediatric Formulation: Design and Development 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (205 p.) 311 $a3-0365-0740-X 311 $a3-0365-0741-8 330 $aThe development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients. 517 $aPaediatric Formulation 606 $aMedicine$2bicssc 610 $adasatinib 610 $aDuchenne muscular dystrophy 610 $acyclodextrin inclusion complex 610 $aphase solubility studies 610 $apaediatric age 610 $aliquid formulation 610 $atumorspheres 610 $aretinoblastoma 610 $atopotecan 610 $apenetration 610 $aconfocal microscopy 610 $apoorly water soluble drug 610 $asolubility enhancement 610 $agrinding 610 $aspray congealing 610 $aneglected tropical diseases 610 $apolymorph 610 $aNorvirŪ 610 $aritonavir 610 $apoorly soluble compound 610 $apediatric 610 $apalatability assessment 610 $abioavailability 610 $aflavor profile 610 $aInterleukin-1 610 $aanakinra 610 $acanakinumab 610 $ainnovative biotechnologies 610 $aautoinflammatory disease 610 $aKawasaki disease 610 $asystemic juvenile idiopathic arthritis 610 $apersonalized medicine 610 $achild 610 $apediatrics 610 $aneonates 610 $aformulation 610 $aproduct development 610 $aformulation development 610 $aoral 610 $aparenteral 610 $atopical 610 $ainhaled 610 $aintra nasal 610 $abiopharmaceutics 610 $aadministration 610 $aexcipient 610 $aNICU 610 $adevice 610 $amedication error 610 $adosage form 610 $amodified release 610 $adrug delivery 610 $apaediatric formulation development 610 $apaediatric dosage forms 610 $achronic myeloid leukemia 610 $atyrosine kinase inhibitors 610 $apediatric age 610 $aimatinib 610 $anilotinb 610 $aponatinib 610 $aOrodispersible formulation 610 $apyrazinamide 610 $apediatric drug delivery 610 $atuberculosis 610 $adesign of experiments 610 $achildren 610 $aedible films 610 $adevelopment 610 $adesign 610 $apaediatric 610 $aage-related 610 $apalatable 610 $ataste-masking 610 $aacceptable 615 7$aMedicine 700 $aDenora$b Nunzio$4edt$01322374 702 $aLopalco$b Antonio$4edt 702 $aDenora$b Nunzio$4oth 702 $aLopalco$b Antonio$4oth 906 $aBOOK 912 $a9910557304003321 996 $aPaediatric Formulation: Design and Development$93034926 997 $aUNINA